Company: KROS
Filing Date: 2025-05-27
Form Type: DEFA14A
Source: 0001104659-25-052890
Chunk: 4

Company: Keros Therapeutics, Inc.
Filing Date: 2025-05-27
Form: DEFA14A
Chunk 4
---
 product candidate,
KER-065, is being developed for the treatment of neuromuscular diseases. Keros’ most advanced product candidate, elritercept (KER-050),
is being developed for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and
in patients with myelofibrosis.

Cautionary Note Regarding Forward-Looking Statements

Statements contained in this press release regarding matters that are
not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of
1995, as amended. Words such as “anticipates,” “believes,” “continue,” “expects,” “enable,”
“potential” and “will” or similar expressions are intended to identify forward-looking statements. Examples of
these forward-looking statements include statements concerning the Annual Meeting and our director nominees, and the intended benefits
of our classified Board structure. Because such statements are subject to risks and uncertainties, actual results may differ materially
from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: whether the objectives
of the strategic alternative review process will be achieved; the terms, structure, benefits and costs of any strategic transaction; the
timing of any transaction and whether any transaction will be consummated at all; the risk that the strategic alternatives review and
its announcement could have an adverse effect on the ability of the Company to retain and hire key personnel and maintain relationships
with partners, suppliers, employees, stockholders and other business relationships and on its operating results and business generally;
the risk the strategic alternatives review could divert the attention and time of the Company’s management; the risk of any unexpected
costs or expenses resulting from the review; the risk of any litigation relating to the review; Keros’ limited operating history
and historical losses; Keros’ ability to raise additional funding to complete the development and any commercialization of its product
candidates; Keros’ dependence on the success of its product candidates, cibotercept, KER-065 and elritercept; that Keros may be
delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar
uses; the risk that circumstances surrounding or leading up to our 2025 Annual Meeting may change; Keros’ ability to obtain, maintain
and protect its intellectual property; and Keros’ dependence on third parties in connection with manufacturing